Find and Pitch Jounalists, Get Your Story Covered

Tags: Glox Therapeutics\bacteriocin development programme\antimicrobial resistance\AMR\Boehringer Ingelheim Venture Fund \

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 6 days ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 28 days ago STAT+: Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings - about 1 month ago STAT+: Pharmalittle: We’re reading about doctors powering telehealth GLP-1 scripts, an FDA hold on a Novavax shot, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 2 months ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 2 months ago STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more - 10 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 11 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 12 months ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - about 1 year ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	A diabetes drug, twice rejected, stumbles again — but its developer persists - 12 days ago Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s - 14 days ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 3 months ago To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach - 8 months ago Black Diamond looks to outwit cancer mutations - 9 months ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	A sickle cell cure exists. But patients need more than just gene therapy. - 17 days ago After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - about 2 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 4 months ago GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that. - 8 months ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - about 1 year ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications - 20 days ago Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’ - 24 days ago Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 3 months ago Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos - 3 months ago Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic - 4 months ago Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials - 5 months ago Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush - 6 months ago J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer - 7 months ago Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials - 7 months ago
5	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	More evidence on GLP-1s and opioid addiction - about 1 month ago
6	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	WuXi looks to sell assets as BIOSECURE Act looms - about 1 month ago
7	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target - 2 months ago STAT+: In another blow, Argenx antibody therapy fails in trial for skin blistering condition - 11 months ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 2 months ago FDA Grants Orphan Drug Designation to AISA-021 for Systemic Sclerosis - 2 months ago Compounded, Counterfeit Semaglutide Poses Severe Risk to Patients - 7 months ago
9	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	European Commission grants orphan drug designation for Vivet’s VTX-806 - 2 months ago
10	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money - 3 months ago

Journalists covering Glox Therapeutics\